Join our daily newsletter At The Bell to receive exclusive market insights
- MGC Pharmaceuticals’ (MXC) Slovenian production and compounding facility has had its Good Manufacturing Practice (GMP) licence renewed for three years
- This is a significant milestone for the company, as it confirms its products comply with the strict European standards
- The renewal allows MGC Pharma to deliver on its target production of 5000 units per month at its Slovenian facility by the start of 2021
- The company can also continue its research, development, production and manufacturing of its CBD and THC products from the same facility
- MGC Pharma is steady on the market today and shares are currently trading for 2.2 cents each
MGC Pharmaceuticals’ (MXC) Slovenian production and compounding facility has had its Good Manufacturing Practice (GMP) licence renewed for three years.
This licence is essential for the production and manufacture of pharmacy grade medicinal products.
It also marks a significant milestone for MGC Pharma, as it confirms its products meet the strict European standards.
The licence also delivers certainty on the company’s capacity to manufacture GMP cannabinoid-based medicinal products such as CannEpil and CogniCann from its facility.
“Authorities usually issue GMP licences with a one-year term so receiving a three-year GMP licence is a great achievement and a real testament to the quality of our products, staff and the facility,” Co-Founder and Managing Director Roby Zomer stated.
The renewal now allows MGC Pharma to deliver on its target production of 5000 units per month at the facility in Slovenia by the start of 2021.
The company can also continue its research, development, production and manufacturing of its CBD and THC products from the same facility.
MGC Pharma is steady on the market today and shares are trading for 2.2 cents each at 1:35 pm AEST.
